Concentration-controlled use of sirolimus associated with reduced exposure of cyclosporine in black recipients of primarily living renal allograft donors: 12-month results

Clinical Transplantation

Volumn 19, Issue 5, 2005, Pages 607-615

  Ferreira, Alexandra N ^a   Machado, Paula G ^a   Felipe, Cláudia R ^a   Motegi, Sofia A ^a   Hosaka, Beatriz H ^a   Tanaka, Márcia K ^a   Kamura, Luciana A ^a   Park, Sung I ^a   Garcia, Riberto ^a   Franco, Marcello ^b   Alfieri, Fernando ^c   Casarini, Dulci E ^a   Tedesco Silva Jr , Hélio ^a,d   Medina Pestana, José O ^a  

^a HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Laboratórios Wyeth Whitehall   (Brazil)

^d Rua Borges Lagoa   (Brazil)

Author keywords

Black patients; Cyclosporine; Immunosuppression; Kidney transplantation; Sirolimus

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; METHYLPREDNISOLONE; PREDNISONE; RAPAMYCIN;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DEATH; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; FEMALE; GRAFT FAILURE; HEMATOMA; HERPES SIMPLEX; HERPES ZOSTER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPEREMIA; HYPERLIPIDEMIA; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; LEUKOPENIA; LIVING DONOR; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MICROEMULSION; MUSCLE CRAMP; NEGRO; PARESTHESIA; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; THROMBOCYTOPENIA; TREMOR; URINARY TRACT INFECTION; VIRUS INFECTION; WOUND INFECTION;

EID: 25144480487     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00331.x     Document Type: Article

References (34)

1. Young CJ, Gaston RS. Renal transplantation in black Americans. N Engl J Med 2000: 343: 1545.
2. Podder H, Podbielski J, Hussein I et al. Sirolimus improves the two-year outcome of renal allografts in African-American patients. Transplant Int 2001: 14: 135.
3. First MR, Schroeder TJ, Monaco AP et al. Cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplantation subpopulations. Clin Transplant 1996: 10: 55.
4. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998: 65: 515.
5. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997: 64: 1277.
6. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000: 356: 194.
7. MacDonald AS, RAPAMUNE Global Study Group A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001: 71: 271.
8. Kahan BD, Keown P, Levy GA et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002: 24: 330.
9. MacDonald A, Scarola J, Burke JT et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000: 22: B101.
10. Kahan BD, Knight R, Schoenberg L et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003: 35: 25S.
11. Cosio FG, Dillon JJ, Falkenhain ME et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int 1995: 47: 1136.
12. Di Marco GS, Andrade MC, Felipe CR et al. Determination of sirolimus blood concentration using high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 2003: 25: 558.
13. Racusen LC, Solez K, Colvin RB et al. The BANFF 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976: 16: 31.
15. Felipe CR, Silva HT Jr, Machado PGP et al. The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. Clin Transplant 2002: 16: 262.
16. Ramos O. Malignant hypertension: the Brazilian experience. Kidney Int 1984: 26: 209.
17. Hricik DE, Anton HA, Knauss TC et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation 2002: 74: 189.
18. Lo A, Egidi MF, Gaber LW et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in deceased renal transplantation. Transplantation 2004: 77: 1228.
19. Gonwa TA, Hricik DE, Brinker K et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002: 74: 1560.
20. Kelly P, Kahan BD. Review: metabolism of immunosuppressant drugs. Curr Drug Metab 2002: 3: 275.
21. Stallone G, Di Paolo S, Schena A et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003: 75: 998.
22. Hricik DE, Knauss TC, Bodziak KA et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003: 76: 938.
23. Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002: 74: 804.
24. Valente JF, Hricik D, Weigel K et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003: 3: 1128.
25. Hricik DE. Hyperlipidemia in renal transplants recipients. Graft 2000: 3: 177.
26. Salvadori M, Bertoni E, Rosati A, Zanazzi M. Post-transplant diabetes mellitus. J Nephrol 2003: 16: 626.
27. Kasiske BL, Snyder JJ, Gilbertson D et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003: 3: 178.
28. Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003: 75: SS3.
29. Cosio FG, Pesavento TE, Kim S et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002: 62: 1440.
30. Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002: 2: 850.
31. Kalil RS, Hudson SL, Gaston RS. Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus? Am J Transplant 2003: 3: 79.
32. Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000: 69: 1252.
33. Johnson RA, Wang X, Ma XL et al. Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol 2001: 75: 6022.
34. Oberbauer R, Kreis H, Johnson RW et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003: 76: 364.